Background: Patients with atrial fibrillation are at risk for various complications, including thromboembolic events. This study involves developing and evaluating a Clinical Decision Support System (CDSS) to select appropriate anticoagulant drug, considering comorbidities, laboratory data, and concurrent medications. The system is based on a streamlined interpretation of the most recent globally accepted clinical guidelines.
Methods: Primarily a semi-structured interview regarding the challenges in the field of thromboprophylaxis for AF and clinical pharmacists and cardiologists' needs in practice was conducted. Then the required data were extracted from the latest guidelines and confirmed by the expert panel. Using Microsoft Visio software each scenario and its corresponding rules were modeled. Dart programming language, the Flutter framework, and the Visual Studio editor were used to develop the application. Finally, the uMARS questionnaire was used to evaluate the application quality.
Results: The selection of the anticoagulants was reported to be the most challenging domain by 78.6% of the participants in the interview. According to the designed algorithms, the application was developed using Asp.net with the Microsoft SQL Server database platform. This CDSS is called ACAFiB-APP, which stands for Anticoagulant in AF Application. The user goes through various calculators and obtains the required data, moreover, the user will choose one or more comorbidities/clinical scenarios. Finally, ACAFiB-APP will represent the proper anticoagulant options with dosing and related considerations. All of the sections in the uMARS questionnaire received acceptable scores.
Conclusions: The CDSS will facilitate the informed selection of anticoagulants for complicated AF cases by considering the patient clinical scenario.
Clinical Trial Number: Not applicable.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1186/s12872-025-04615-w | DOI Listing |
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889798 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Assessing GPT-4's accuracy in answering clinical pharmacological questions on pain therapy.
Br J Clin Pharmacol
March 2025
Faculty of Health, Department of Medicine, Witten-Herdecke University, Witten, Germany.
Aims: This study aimed to evaluate the accuracy and completeness of GPT-4, a large language model, in answering clinical pharmacological questions related to pain therapy, with a focus on its potential as a tool for delivering patient-facing medical information. The objective was to assess its reliability in delivering medical information in the context of pain management.
Methods: A cross-sectional survey-based study was conducted with healthcare professionals, including physicians and pharmacists.
Novel predictors of infection-related rehospitalization in older patients with heart failure in Japan.
Geriatr Gerontol Int
March 2025
Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Aim: Rehospitalization of patients with heart failure (HF) incurs high health care costs and increased mortality. Infection-related rehospitalizations in patients with HF occur frequently, and the risk increases with age. This study aimed to identify the factors associated with infection-related rehospitalizations in older patients with HF.
View Article and Find Full Text PDFUnlocking the Gates: A Novel Diagnostic Molecule for Quantifying Efflux Levels in Gram-Positive Bacteria.
Adv Healthc Mater
March 2025
Aix Marseille Université, INSERM, SSA, MCT, Marseille, 13385, France.
Efflux-mediated antibiotic resistance poses a significant global threat, affecting diverse bacterial species. Clinicians recognize the danger of efflux mechanisms during antibiotic treatment, yet precise diagnostic tools remain unavailable. The antibiogram currently infers abnormal efflux pump activity in clinical isolates, which is subsequently confirmed through transcriptomic or genomic analysis.
View Article and Find Full Text PDFDose Ranging in Pediatric Drug Development Trials Submitted to the US FDA 2012-2020.
J Clin Pharmacol
March 2025
Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Dose selection is a critical process within pediatric drug development and dose-ranging studies are integral to establish a reasonable dose. The objective of this analysis was to examine the dose-ranging trials utilized in pediatric drug development and to determine (1) the dose-ranging strategies that were used in all available pediatric dose-ranging studies, (2) the success of achieving pediatric labeling in those submissions to the US Food and Drug Administration, and (3) ethical aspects of providing a prospect of direct benefit to pediatric patients in dose-ranging studies. Of the 275 programs that previously surveyed pediatric drug development programs from 2012 to 2020, it was determined that dose-ranging studies were used for 97 (35.
View Article and Find Full Text PDFA proximal policy optimisation algorithm-based algorithm for cardiovascular disorders detection.
J Med Eng Technol
March 2025
College of Basic Medical, North China University of Science and Technology, Tangshan, China.
Cardiovascular diseases (CVDs) significantly impact athletes, impacting the heart and blood vessels. This article introduces a novel method to assess CVD in athletes through an artificial neural network (ANN). The model utilises the mutual learning-based artificial bee colony (ML-ABC) algorithm to set initial weights and proximal policy optimisation (PPO) to address imbalanced classification.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!